Identification of Biomarkers for Obstructive Sleep Apnoea Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02043483|
Recruitment Status : Completed
First Posted : January 23, 2014
Last Update Posted : February 18, 2015
Untreated Obstructive Sleep Apnea Syndrome (OSAS) has long-term complications, namely metabolic imbalances (obesity, dislipidemia, type 2 diabetes mellitus). Until now, no molecular markers for this physiopathological connection have been identified.
This project aims to determine non-invasive biomarkers that may allow better comprehension of the metabolic consequences of OSAS, as well as assess the effect of Continuous positive airway pressure (CPAP) on these metabolic parameters.
This project will integrate the clinical, metabolic, genetic/proteomic and biologic systems to further explore the mechanisms behind OSAS, as well as the effect of the treatment with CPAP.
|Condition or disease|
|Obstructive Sleep Apnoea Syndrome|
|Study Type :||Observational|
|Estimated Enrollment :||120 participants|
|Observational Model:||Case Control|
|Official Title:||Obstructive Sleep Apnoea and Associated Metabolic/Cardiovascular Disorders: Understanding Mechanisms Towards Early Diagnosis and Prognosis|
|Study Start Date :||October 2012|
|Primary Completion Date :||December 2014|
|Study Completion Date :||December 2014|
Patients with moderate/severe OSAS will be treated with CPAP
Patients with snoring will not be subject to treatment with CPAP
- Percentage of patients with clinical improvement [ Time Frame: 6 months ]Treatment efficacy of CPAP will be assessed at the end of treatment through a clinical observation.
- Frequency of occurence of biomarkers [ Time Frame: 6 months ]Using Mass Spectrometric Immunoassay, we will identify which biomarkers have a positive association with long-term treatment effect.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02043483
|Centro Hospitalar Lisboa Norte|
|Principal Investigator:||Amélia Feliciano, MD||Centro Hospitalar Lisboa Norte|